Corcept Therapeutics stock plunges after loss in patent battle with with Teva
Dr_Microbe/iStock through Getty Photos Corcept Therapeutics (NASDAQ:CORT) plummeted 38% in after-hours buying and selling on Friday after a loss in a patent trial with Teva Prescribed drugs (NYSE:TEVA) over a ...